News

MorphoSys and OncoMed had entered into a license agreement in June 2006 to use MorphoSys’ HuCAL technology in the research and development of human therapeutic antibodies for the

Particle Sciences and Celanese EVA Performance Polymers are working to provide Particle Sciences with preferred access to VitalDose EVA polymer in early stage projects. Particle Sciences New Technologies

The company posted a net loss of $32.1m, or $0.57 per diluted share for the first quarter of 2011, compared to $34.08m, or $0.66 per diluted share, for

In clinical studies, Rasilamlo demonstrated reductions in blood pressure than Rasilez and amlodipine alone. The study results suggested that the use of single-pill combinations like Rasilamlo can provide

The US net sales increased 5% to $3.3bn in the first quarter of 2011 compared to the same period in 2010. International net sales increased 3%, or 1%

MediSpend is a secure hosted SaaS solution, which enables pharmaceutical, medical device, and biotechnology companies to track, aggregate, and report all spend data consistent with state and federal

For the first quarter of 2011, the company’s net income was EUR1.29bn, compared to EUR1.79bn in the prior year period. The company has generated gross profit of EUR5.83bn,

INNO-206 is intended to control the release of chemotherapeutic doxorubicin and to preferentially target tumors, which the company believes may make it more effective and less toxic in

The company posted a gross profit of $337.91m for the first quarter of 2011, compared to $343.46m for the same period in 2010. For the first quarter of